CBD Pet Market - Global Industry Size, Share, Trends, Opportunity and Forecast, Segmented By Animal Type (Dogs, Cats, Others), By Indication (Joint Pain, Anxiety/Stress, Epilepsy, General Health/Wellness, Other Indications), By Distribution Channel (Pet Specialty Stores, E-Commerce, CBD Stores, Others), By Region and Competition, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 256.48 Million
CAGR (2026-2031)	12.01%
Fastest Growing Segment	Dogs
Largest Market	North America
Market Size (2031)	USD 506.52 Million

Market Overview

The Global CBD Pet Market will grow from USD 256.48 Million in 2025 to USD 506.52 Million by 2031 at a 12.01% CAGR. The Global CBD Pet Market encompasses hemp-derived cannabidiol formulations such as oils, chews, and topicals designed to alleviate anxiety, pain, and inflammation in companion animals. Primary drivers fueling this sector include the rising humanization of pets and a growing consumer preference for natural holistic health solutions over traditional pharmaceuticals. This shift is supported by safety data which encourages adoption. According to the National Animal Supplement Council, in 2024, the rate of adverse events for CBD products was found to be 2.1 per one million administrations, reinforcing consumer confidence in these alternative therapies.

However, regulatory ambiguity remains a formidable challenge impeding broader market expansion. Inconsistent legal frameworks and the absence of federal approval for CBD as a veterinary feed additive create compliance burdens and deter veterinary professionals from formally prescribing these products. This lack of standardization complicates interstate commerce and limits the ability of major retailers to fully embrace the category.

Key Market Drivers

The rising trend of pet humanization and premiumization serves as a foundational catalyst for the Global CBD Pet Market, fundamentally altering purchasing behaviors. As owners increasingly view their companions as integral family members, they are more willing to invest in high-quality, wellness-focused products that mirror human health trends. According to Forbes Advisor, October 2025, 51% of pet owners consider their pets to be as much a part of their family as a human family member. This deep emotional bond drives the demand for premium care options, contributing significantly to the sector's financial vitality. According to the American Pet Products Association, March 2025, in the '2025 State of the Industry Report', total U.S. pet industry expenditures reached $152 billion in 2024, underscoring the massive economic scale of this owner-pet relationship that CBD brands are actively leveraging to position their products as essential wellness staples.

Simultaneously, the increasing prevalence of chronic and age-related pet ailments creates a direct pathway for the adoption of natural remedies. Owners are actively seeking holistic alternatives to conventional pharmaceuticals to manage conditions such as mobility issues and behavioral stress, which are primary use cases for cannabidiol. According to the American Pet Products Association, August 2024, in the '2024 Dog and Cat Report', the use of calming products has grown by 168% for dogs since 2018. This surge highlights a specific consumer pivot towards anxiety-relief solutions, directly benefiting CBD formulations designed to mitigate stress. Consequently, as the demand for functional anxiety and pain management grows, the market for CBD-infused oils and treats continues to expand to meet these therapeutic needs.

Download Free Sample Report

Key Market Challenges

Regulatory ambiguity constitutes a primary obstacle restricting the commercial scalability of the global CBD pet market. The absence of federal approval for CBD as a feed additive generates significant liability risks, which discourages national retailers from stocking these products. This exclusion from high-traffic sales channels forces distribution into fragmented online and specialty markets, thereby limiting consumer visibility and accessibility. Furthermore, the lack of federal oversight discourages veterinary professionals from endorsing these therapies, severing a crucial link between medical advice and product adoption.

The restriction on market maturity persists despite clear indications of consumer demand. According to the American Pet Products Association, in 2024, 12% of dog owners utilized CBD products for their pets. While this participation demonstrates a viable customer base, the continued legal uncertainty acts as a bottleneck, preventing the sector from capitalizing on this interest to achieve mass adoption. Without a standardized framework to assure safety and legality, the industry remains unable to unlock its full growth potential through mainstream retail integration.

Key Market Trends

The adoption of nano-emulsion technology is transforming product efficacy by addressing the inherent low bioavailability of traditional lipid-based cannabinoids. Manufacturers are increasingly utilizing this advanced processing method to break down CBD oil into microscopic particles, significantly increasing the surface area for absorption within a pet's digestive tract. This innovation allows for water-soluble formulations that ensure more consistent therapeutic outcomes and faster onset times compared to conventional tinctures. According to Frontiers in Veterinary Science, April 2024, in the 'Pharmacokinetics behavior of four cannabidiol preparations following single oral administration in dogs', a study revealed that nano-emulsion based formulations achieved maximum plasma concentrations in the range of 92–314 μg/L within three hours, outperforming other delivery methods in rapid absorption.

Simultaneously, the market is undergoing a phase of consolidation through strategic acquisitions, signaling the entry of established animal health and equity firms into the space. This trend highlights a shift from fragmented, small-scale operations toward a matured landscape where capital investment drives scalability and distribution reach. Large entities are acquiring successful supplement brands to diversify portfolios and capitalize on the established trust these niche players have built. According to Petfood Industry, December 2024, in the 'Pet industry M&As set to surge in 2025', the sector's financial evolution was highlighted by the acquisition of FoodScience pet supplements by private equity investors in late November, exemplifying the heightened institutional interest in high-quality nutritional assets.

Segmental Insights

The Dogs segment identifies as the fastest-growing category within the Global CBD Pet Market, primarily driven by the rising prevalence of canine anxiety and musculoskeletal disorders such as osteoarthritis. Pet owners are increasingly seeking alternative therapeutic solutions to manage pain and behavioral issues, fueled by the widespread trend of pet humanization and heightened awareness of animal wellness. This demand is further supported by the development of canine-specific formulations, including treats and oils, which facilitate easier administration. Additionally, ongoing clinical research into cannabinoid efficacy is gradually strengthening confidence among consumers and veterinary professionals regarding the benefits of these integrative treatments.

Regional Insights

North America maintains a dominant position in the global CBD pet market, primarily due to supportive legislation and high product adoption rates. The United States Agricultural Improvement Act of 2018 removed hemp from the federal list of controlled substances, effectively legalizing hemp-derived components and enabling widespread product manufacturing. This regulatory framework allows companies to distribute wellness supplements through diverse retail channels, significantly increasing accessibility for pet owners. Additionally, the strong trend of pet humanization across the region drives consistent demand for natural therapeutic options, ensuring North America remains the primary revenue generator in this sector.

Recent Developments

• In August 2024, Extract Labs announced that its "Fetch" line of pet CBD products had officially received the Quality Seal from the National Animal Supplement Council (NASC). This certification was awarded following a rigorous independent audit of the company's manufacturing facilities, quality control protocols, and product labeling to ensure compliance with stringent industry standards. The company stated that achieving this milestone distinguished its tinctures and treats in a crowded marketplace, offering consumers verified assurance regarding the safety, potency, and consistency of its hemp-derived pet supplements.
• In March 2024, Pet Releaf, a leading player in the plant-based pet CBD sector, expanded its product portfolio by unveiling a new line of wellness supplements at the Global Pet Expo. The company introduced "Pet Releaf Naturals," a collection of non-hemp products including fish-free Omega 3s and postbiotics, designed to complement its existing CBD offerings. This strategic launch was intended to provide a holistic wellness regimen for dogs and cats, allowing pet owners to address multiple aspects of animal health using sustainable, plant-based ingredients alongside their standard cannabinoid regimen.
• In March 2024, CV Sciences, Inc. broadened its presence in the animal health sector with the launch of two new products under its +PlusCBD Pet brand: Hip and Joint Health Chews and Calming Care Chews. These soft chews were formulated with THC-free hemp extract combined with functional ingredients such as glucosamine, turmeric, and chamomile to target anxiety and mobility issues in dogs. The company emphasized that these new offerings were supported by a landmark safety study conducted by the National Animal Supplement Council, which provided critical data validating the safety of long-term cannabinoid use in healthy dogs.
• In January 2024, ElleVet Sciences announced the results of comprehensive clinical studies that demonstrated the efficacy of its proprietary CBD and CBDA formulations for a wider range of pet health conditions. While the company had previously established the effectiveness of its products for canine mobility, this new research validated their use for cognitive support, stress relief, and dermatological issues. Following these findings, the company updated its product packaging to include condition-specific dosing instructions, aiming to assist veterinarians and pet owners in administering the supplements more effectively for these newly verified indications.

Key Market Players

• Honest Paws
• Canna-Pet
• FOMO Bones
• Pet Releaf
• HolistaPet
• Joy Organics
• Wet Noses Inc.
• CBD Living
• Petstock Pty Ltd
• Petco Animal Supplies, Inc.

By Animal Type	By Indication	By Distribution Channel	By Region
Dogs Cats Others	Joint Pain Anxiety/Stress Epilepsy General Health/Wellness Other Indications	Pet Specialty Stores E-Commerce CBD Stores Others	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global CBD Pet Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• CBD Pet Market, By Animal Type:

• Dogs
• Cats
• Others

• CBD Pet Market, By Indication:

• Joint Pain
• Anxiety/Stress
• Epilepsy
• General Health/Wellness
• Other Indications

• CBD Pet Market, By Distribution Channel:

• Pet Specialty Stores
• E-Commerce
• CBD Stores
• Others

• CBD Pet Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE